Insider buying last 90 days
No open-market insider purchases were filed for KYMR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Kymera Therapeutics moves this week on Q3 2026 results, which showed a net loss of $132 million as the company prioritizes pipeline progress for protein degradation candidates KT-579 and KT-621 over near-term profitability, alongside an EPS of -$1.32 that missed estimates by $0.05. Shares touched an all-time high of $130.48 before falling 5.97% on 5 November to close at $128.12, then recovering into the latest close. Barclays maintained its Overweight rating and raised its price target to $170 from $139, citing continued confidence in the clinical-stage story.
The stock closes at $138.86, up 5.4%, sitting above both its 50-day average of $116.08 and 200-day average of $98.26, with the 50-day above the 200-day in a supportive trend structure. The GekkoIndex reads 43, placing it in the Distribution zone. Price sits 18.7% above Gekko Fair Value of $116.98, a notable premium to that benchmark.
The next earnings date falls on 25 February 2027, 107 days out and beyond a typical 20-trading-day holding window. Seasonality over the next 20 trading days has averaged a 12.7% return across 5 years, though gains occurred in only 2 of those years. Smart money activity shows no insider, Congress or unusual options signals in their respective windows. Analyst sentiment remains heavily tilted toward buy ratings, with a consensus target of $144.57.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Kymera Therapeutics scores 3 supportive, 2 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed1 headwind
Above 50 and 200-day
Close $127.57 is above the 50-day ($117.13) and 200-day ($99.45) averages, and the 50-day is above the 200-day.
See the chart53.7, Neutral
Reading 53.7 is in the Neutral zone.
See the GekkoIndex8.2% above
Price is 8.2% above Gekko Fair Value (more than 5% above).
See fair valueLeans bullish
Last 30 days: 1 unusual options signal.
See smart moneyReports in 102 days
Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.
See earnings+7.0% on average
From this point in the calendar, the next 20 trading days averaged +7% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Kymera Therapeutics closed at $127.57 on Nov 13, 2026, +100.8% over the past year, inside a 52-week range of $61.50 to $142.92.
Use the left and right arrow keys to read daily values.
Put KYMR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Kymera Therapeutics is a biopharmaceutical business focused on building small molecule drugs that tap into a natural cellular process for clearing proteins tied to illness. Rather than blocking disease proteins, its compounds are designed to flag them for removal using pathways the body already has, and this degradation-based approach is the throughline across its research efforts and candidate therapies.
The company runs several drug programs aimed at different conditions. One candidate, targeting IRAK4, has reached Phase I testing and is being explored for conditions such as rheumatoid arthritis, atopic dermatitis, hidradenitis suppurativa, generalized pustular psoriasis, and macrophage activation syndrome. A separate effort, IRAKIMiD, is being developed for a form of diffuse large B cell lymphoma linked to MYD88 mutations. The STAT3 program looks at blood cancers, solid tumors, fibrosis, and autoimmune conditions, while a fourth program centered on MDM2 is also being pursued for blood cancers and solid tumors.
Kymera Therapeutics traces its founding to 2015 and operates out of Watertown, Massachusetts. Its stock trades on the NASDAQ exchange under the symbol KYMR.
Kymera Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.7, in the Neutral zone, up 8.5 points over five sessions.
Up 8.5 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 23 | +6.4% | +24.6% | ||
| Accumulation | 208 | +1.9% | +7.7% | ||
| Neutral (current zone) | 396 | +0.9% | +3.2% | ||
| Distribution | 71 | +2.8% | +4.7% | ||
| Selling | 4 | Too few readings yet | |||
Average KYMR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Kymera Therapeutics trades 8.2% above Gekko Fair Value of $117.93, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Kymera Therapeutics shares are worth, recalculated every trading day.
$117.93
Gekko Fair Value, Nov 14, 2026
8.2% Overvalued
At the end of Aug 2026 the price was 5.4% below the estimate.
No open-market insider purchases were filed for Kymera Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for KYMR in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in KYMR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
1signal, 83% of the flagged premium in calls.
Latest: Bullish flow on Nov 10, $3.62M in unusual premium.
0of the funds Gekko tracks hold KYMR.
Kymera Therapeutics reports on Feb 25, 2027, before the open (102 days away), and beat the EPS estimate in 4 of its last 8 reports.
Feb 25, 2027
Expected before the open, 102 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | −$0.62 est −$0.64 | $65.00M est $32.78M | +1.9% |
| Apr 30, 2026 | −$0.71 est −$0.86 | $34.37M est $8.27M | −1.0% |
| Feb 26, 2026 | −$0.97 est −$0.78 | $2.87M est $15.05M | +0.7% |
| Nov 4, 2025 | −$0.90 est −$0.71 | $2.76M est $14.45M | +0.3% |
| Aug 11, 2025 | −$0.95 est −$0.83 | $11.48M est $17.13M | −1.8% |
| May 9, 2025 | −$0.82 est −$0.92 | $22.10M est $12.38M | +4.5% |
| Feb 27, 2025 | −$0.88 est −$0.76 | $7.39M est $16.68M | −11.3% |
| Oct 31, 2024 | −$0.82 est −$0.83 | $3.74M est $15.21M | −2.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Kymera Therapeutics is $145.22, +13.8% from the last close, from 15 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 15 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 3 | Canaccord Genuity | $129 | +1.1% |
| Nov 2 | Barclays | $170 | +33.3% |
| Nov 2 | Leerink Partners | $140 | +9.7% |
| Nov 1 | BTIG | $139 | +9.0% |
| Oct 30 | Morgan Stanley | $150 | +17.6% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Kymera Therapeutics averaged +7.0% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.0% | 2 of 5 |
| Next 10 trading days | +0.2% | 2 of 5 |
| Next 15 trading days | +9.5% | 2 of 5 |
| Next 20 trading days | +7.0% | 2 of 5 |
| Next 30 trading days | +8.9% | 3 of 5 |
For scale, KYMR’s typical 20-trading-day move in either direction is about 11.9%.
Kymera Therapeutics’s market cap is $10.89B and revenue of $102.2M over the last twelve months.
Coverage of Kymera Therapeutics this week reads neutral: 1 positive, 4 neutral and 0 negative headlines.
Kymera Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
Kymera Therapeutics’s market cap is $10.89B at the Nov 13, 2026 close of $127.57, with 85.37M shares outstanding.
The consensus analyst 12-month price target for Kymera Therapeutics is $145.22, +13.8% from the last close. Of the 15 firms that rated the stock in the last 90 days, 14 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Kymera Therapeutics is overvalued: the Nov 13, 2026 close of $127.57 is 8.2% above Gekko Fair Value of $117.93. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Kymera Therapeutics is expected to report on Feb 25, 2027, before the market opens (102 days away). Analysts expect earnings of −$1.29 per share on revenue of $253K. Kymera Therapeutics beat the earnings estimate in 4 of its last 8 reports, moving 3% on average across the report.
Kymera Therapeutics’s 52-week high is $142.92 and its 52-week low is $61.50; it closed at $127.57 on Nov 13, 2026, +100.8% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (trend, smart money and earnings risk), 2 as mixed (gekkoindex and seasonality) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in Kymera Therapeutics over the last 30 days, with $3.00M of flagged premium in calls and $625K in puts. The latest, bullish flow, was on Nov 10, 2026 with $3.62M in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.